Company ProfilePremium

Jiangsu SOPO (Group) Co., Ltd.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jiangsu SOPO (Group) Co., Ltd. - Company showcase

Year Founded & Workforce

1958

2,039 Employees

Jiangsu SOPO (Group) Co., Ltd. logo

Jiangsu SOPO (Group) Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jiangsu SOPO (Group) Co., Ltd. Overview

ItemDetail
Entity profiledJiangsu SOPO Chemical Co., Ltd. (江苏索普化工股份有限公司)
Parent / named entityJiangsu SOPO (Group) Co., Ltd. (江苏索普(集团)有限公司), unlisted SOE
Ultimate controllerZhenjiang Municipal People's Government SASAC
Former namesGroup predecessor: Zhenjiang Chemical Plant (镇江化工厂)
Founding year1958 (group predecessor)
ListingShanghai Stock Exchange main board, A-shares, since 1996 (IPO raised RMB 87M per 36Kr; listing month variously reported as Aug or Sep 1996)
Ticker600746 (SSE); also tradable via Shanghai–Hong Kong Stock Connect
ISIN—
Incorporation jurisdictionJiangsu Province, People's Republic of China
Registered addressNo. 88 Qiusuo Road, Jingkou District, Zhenjiang, Jiangsu 212006
Office addressNo. 101 Qiusuo Road, Jingkou District, Zhenjiang, Jiangsu 212006
Telephone / email0511-88995001 / jssopo@sopo.com.cn
Websitewww.sopo.com.cn
Fiscal year end31 December
Total shares1,167,842,884 A-shares (since April 2021), all now tradable
Controlling shareholder stake867,603,652 shares, 74.29% (May 2024 disclosure)
Employees2,039 (Simply Wall St) / 2,058 (CFI.cn)
AuditorBDO China Shu Lun Pan CPAs (立信会计师事务所), auditor since FY2024; standard unqualified opinions for FY2024 and FY2025
ChairmanShao Shouyan (邵守言)
General ManagerChen Zhilin (as listed by Simply Wall St; not cross-verified in a primary filing)
Industry (CSRC)C26 Chemical raw materials and chemical products manufacturing
Share priceRMB 6.56 (close 31 Jul 2026); RMB 5.22 (13 Jul 2026, before limit-up on 14 Jul)
Market capApprox. RMB 7.66bn at RMB 6.56 x 1,167.84M shares (derived, 31 Jul 2026)

Jiangsu SOPO Chemical is a Zhenjiang-based, state-controlled commodity chemical producer whose economics are dominated by a single product: acetic acid made by methanol carbonylation from coal-derived syngas. It operates 1.2 million tonnes per year of acetic acid and 250,000 tonnes per year of ethyl acetate capacity, placing it among China's larger acetic acid producers, alongside a smaller chlor-alkali, sulfuric acid and fine-chemicals platform held in its wholly owned subsidiary SOPO New Materials. Earnings are highly cyclical: net profit swung from RMB 2.40bn in FY2021 to RMB 18.8M in FY2023 as Chinese acetic acid capacity expanded past 15 million tonnes. Management's response is downstream integration into vinyl acetate monomer (VAM), ethylene-vinyl acetate (EVA) and dimethyl carbonate (DMC), funded by a proposed RMB 1.6bn private placement. The equity is a high-beta, low-float-relative-to-parent vehicle on the acetic acid cycle, with a 74% SOE parent.


Company's own description (FY2025 annual report, paraphrased)

In its FY2025 annual report summary (published 18 April 2026), the company states that its principal business, together with its subsidiaries, is the production and sale of chemical raw materials, chiefly acetic acid and derivatives, and chlor-alkali products. It describes acetic acid and its derivatives as basic chemical feedstocks, handled as liquids in tanks, used across dyes, printing and dyeing, film, solvents, pharmaceuticals and pesticides, and notes that in China acetic acid goes mainly into PTA, acetate esters, vinyl acetate and acetic anhydride.

The company states that its methanol carbonylation route is the mainstream industry technology, that China is the world's largest acetic acid producer with over half of global capacity, and that the business, as a branch of coal chemicals, is cyclical and driven by the macro cycle and upstream/downstream supply-demand. The parent company itself produces glacial acetic acid, ethyl acetate, sulfuric acid and ADC blowing agent; the wholly owned subsidiary Jiangsu SOPO New Materials Technology Co., Ltd. produces chlor-alkali, sulfuric acid, chlorobenzenes, fatty alcohols and chloroacetic acid.

Operationally, the company describes an "amoeba" management model focused on innovation and cost, transparent open procurement with price comparison, and a sales model that is primarily direct sales supplemented by distributors, with an effort to raise the direct-customer share and develop self-operated exports.

Independent characterisation

SOPO Chemical is best understood as a single-product, coal-to-acetic-acid spread business with a small, lower-margin inorganic chemicals tail. The acetic acid and derivatives line generated roughly RMB 1.06–1.07bn of revenue per quarter in Q4 2024 and Q1 2025, against roughly RMB 78–85M for sulfuric acid and derivatives in the same quarters (quarterly operating-data announcements). On those figures acetic acid and derivatives represent roughly 85–90% of quarterly operating revenue, with the remainder split across sulfuric acid, chlor-alkali and fine chemicals.

The company is integrated backward into methanol (methanol output rose 64.94% in FY2024 per the General Manager's report), which is an intermediate for acetic acid and the planned DMC unit. It is not integrated into coal mining, so it is a buyer of coal and therefore benefits when coal prices fall faster than acetic acid prices (as the FY2025 report notes occurred).

Business and revenue model

DimensionCharacterisation
Revenue model~100% product sales; no material service, subscription or licensing revenue
Value-chain positionMid-stream: coal/syngas → methanol → acetic acid → ethyl acetate; inorganic chain: sulfur → sulfuric acid; salt → caustic soda/chlorine → chlorobenzenes, chloroacetic acid
PricingSpot/contract prices referenced to Chinese domestic commodity markets; price-taker
Customer typesPTA producers, acetate ester makers, VAM producers, acetic anhydride producers, pharmaceutical and agrochemical intermediates makers, textile/dye users, traders
Sales channelMainly direct, supplemented by distributors; developing self-operated exports
End-marketsPolyester (via PTA), coatings and solvents (esters), adhesives and films (VAM), pharma, pesticides, dyes, light industry, construction materials, power, electronics, food processing
Other revenue"Other revenue" of RMB 86.5M in FY2025, down from RMB 404.2M in FY2021 (StockAnalysis)

Strategy

Stated strategy themes. The FY2024 General Manager's report framed the year around accelerating "new quality productive forces" and high-quality development, with safety, environmental compliance, cost reduction and capacity utilisation as operating pillars. The FY2025 report emphasises technical retrofits, run optimisation and cost reduction.

Downstream integration. The central strategic initiative is extending from acetic acid and methanol into higher-value products:

Medium-term financial targets: none publicly disclosed.

Products & Services

Acetic acid and derivatives (parent company)

ProductDescriptionCapacityKey uses / customersNotes
Glacial acetic acidMethanol carbonylation of CO; coal-based syngas1,200,000 t/yrPTA, acetate esters, VAM, acetic anhydride, pharma, pesticides, dyesCore earnings driver; ranks among leading Chinese producers
Ethyl acetateEsterification of acetic acid with ethanol250,000 t/yrSolvents for coatings, inks, adhesives, pharmaCaptive acetic acid consumption
MethanolIntermediate from syngas—Captive feed to acetic acid; planned DMC feedFY2024 output +64.94% YoY

Other chemicals (mainly SOPO New Materials)

ProductCapacityUses
Sulfuric acid and downstream series600,000 t/yrFertiliser, metals, chemicals
Caustic soda (chlor-alkali)200,000 t/yrAlumina, pulp, textiles, chemicals
Dichlorobenzene30,000 t/yrIntermediates, pesticides, deodorants
Chloroacetic acid50,000 t/yrCarboxymethyl cellulose, herbicides, pharma
2-chloro-4-aminotoluene (邻氯对氨基甲苯)5,000 t/yrDye and pesticide intermediates
Fatty alcohols—Surfactants
ADC blowing agent (azodicarbonamide)Small; volumes lowFoamed plastics and rubber; now mainly serves legacy customers and blended products

Pipeline products (pre-revenue)

ProjectScaleTechnologyStatus
VAM and EVA integrated project, phase 1Not specified in sources reviewedDuPont ethylene-route VAM licence (company claims it is the only DuPont-licensed VAM technology in China)Licence acquired from SOPO Group 2024; seeking placement funding
200 kt/yr DMC100 kt/yr industrial grade + 100 kt/yr electronic gradeUBE (Japan) technologyTotal investment RMB 1.544bn; RMB 700M from placement; 3-year build

Pricing for all products is market-referenced commodity pricing; no list prices are disclosed.

Financial Narrative

Source: StockAnalysis.com standardised statements (pulled 31 Jul 2026), cross-checked against company announcements for FY2024 and FY2025 revenue and net profit, which match.

Income statement

FY2021 EPS is overstated slightly vs reported weighted EPS because 119.5M shares were issued in April 2021. FY2021 DPS is the RMB 2 per 10 shares paid in 2022 per Jiemian.

Margins

Revenue CAGR FY2021–FY2025 (derived): approx. -7.5% per year. Implied FY2020 revenue (from 110.89% FY2021 growth) is approx. RMB 3.80bn, giving a FY2020–FY2025 CAGR of roughly +9%, consistent with Simply Wall St's 10.5% 5-year revenue growth figure.

Balance sheet (selected)

At 31 March 2026, cash had fallen to RMB 643M and the company moved to net debt of RMB 115M (StockAnalysis), the first net-debt position in the five-year series. The liability-to-asset ratio was 17.69% at 30 June 2024 (Jiemian), indicating a conservatively financed balance sheet.

Cash flow (selected)

H1 2024 operating cash inflow was RMB 155M, up RMB 161M YoY (Jiemian).

Ratios

ROE was reported at 4.5% on a trailing basis in mid-2025 by Simply Wall St.

Commentary

The five-year record is a textbook commodity cycle. FY2021 was exceptional: acetic acid prices in China spiked on supply outages and strong PTA/VAM demand, lifting gross margin to roughly 42% and net profit to RMB 2.40bn. That boom attracted a wave of capacity; by mid-2025 Chinese capacity exceeded 15 million tonnes after more than 2 million tonnes were added in H1 2025 alone, while downstream demand grew only 5–7% (Jiemian, Aug 2025). Gross margin compressed to single digits from FY2023.

FY2024 was a volume-led recovery: acetic acid and derivatives output rose 31.81% and methanol 64.94%, lifting revenue 18.4% and net profit to RMB 213M. FY2025 reversed: management cited heavy new industry capacity, a further fall in acetic acid prices, and a major plant turnaround that reduced output and sales slightly, partly offset by lower coal costs. Net profit fell to RMB 88.4M; with 9M 2025 profit of RMB 126M, Q4 2025 was loss-making (approx. RMB -38M, derived).

The notable cost-side trend is R&D, which more than halved from RMB 271M (FY2022) to RMB 109M (FY2025). SG&A has also been cut. The balance sheet, while still conservative, has shifted from a large net cash pile (RMB 1.88bn in FY2021) toward modest net debt at Q1 2026, as dividends, the licence purchase, project pre-spend and receivables growth (AR up 36% in FY2025) absorbed cash.

The inflection into 2026 is price-driven: H1 2026 net profit is guided at RMB 220–250M, implying Q2 2026 of RMB 186–216M versus RMB 34M in Q1, attributed by the company to higher year-on-year prices of its main products.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipActivities

Zhenjiang SASAC

Actual controller

State ownership

Jiangsu SOPO (Group) Co., Ltd.

Controlling shareholder, 74.29% (May 2024)

Holding company; also owns SOPO Chemical Construction Engineering Co. (petrochemical construction, pressure-vessel qualifications) and SOPO Engineering Technology Co. (chemical design)

Jiangsu SOPO Chemical Co., Ltd. (600746)

Listed company

Acetic acid, ethyl acetate, sulfuric acid, ADC blowing agent, methanol (intermediate)

Jiangsu SOPO New Materials Technology Co., Ltd.

100% subsidiary

Chlor-alkali, sulfuric acid series, chlorobenzenes, fatty alcohols, chloroacetic acid; designated developer of VAM/EVA project

Product Lines

Product line (CNY Mn, quarterly)Q4 2024Q1 2025

Acetic acid and derivatives revenue

1,059.061,071.09

Sulfuric acid and derivatives revenue

77.8085.02

Product line volume (tonnes, quarterly)

Product line volume (tonnes, quarterly)Q4 2024Q1 2025

Acetic acid and derivatives output

455,526452,424

Acetic acid and derivatives sales

393,831391,230

Sulfuric acid and derivatives output

224,091225,314

Sulfuric acid and derivatives sales

224,616226,801

Revenue by Segment

Segment (CNY Mn)FY2023FY2024FY2025

Total revenue as reported

5,4066,4035,856

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue as reported (CNY Mn)

8,0047,1725,4066,4035,856

Operating revenue (CNY Mn)

7,5996,9915,2296,3465,770

Revenue growth (%)

110.89-10.39-24.6218.43-8.53

Cost of revenue (CNY Mn)

4,6716,1104,9965,8425,536

Gross profit (CNY Mn)

3,3331,062410560320

SG&A (CNY Mn)

139.39197.68200.49178.00152.92

R&D expense (CNY Mn)

256.33270.77199.92146.96109.29

Total operating expenses (CNY Mn)

465.78514.07413.36320.38261.93

Operating income, derived (CNY Mn)

2,867548-324058

Net income attributable (CNY Mn)

2,402505.1418.83213.5988.38

Net income growth (%)

938.45-78.97-96.271,034.14-58.62

Basic EPS, derived on 1167.84M shares (MYR Bn)

2.060.430.020.180.08

Dividend per share (MYR Bn)

0.20——0.050.04

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

Metric (%)FY2021FY2022FY2023FY2024FY2025

Gross margin, derived

41.614.87.68.75.5

Operating margin, derived

35.87.6-0.13.71.0

Net margin

30.07.00.353.31.5

R&D / revenue, derived

3.23.83.72.31.9

Key Financials and Per-Share Data

Metric (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Cash and equivalents

1,675963.27903.31,0991,000

Cash and short-term investments

2,026983.31903.31,1311,000

Accounts receivable

551.02412.83445.75530.73722.54

Inventory

613.42541.01477.08544.44453.75

Goodwill

41.8141.8141.8141.8141.81

Total debt, derived

1500328335733

Net cash (positive = net cash)

1,876983.31575.54796.42266.64

Net cash per share (MYR Bn)

1.650.840.490.690.23

Cash Flow

Metric (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Net debt issued (repaid)

-536.3-138.4320.33-35.38401.24

Net change in cash

891.62-284.77-159.15-234.65316.91

Data Point Details

Data pointValueDate / source

Share price

RMB 6.56

31 Jul 2026, StockAnalysis

Share price

RMB 5.22

13 Jul 2026, STCN

Share price

RMB 7.81

13 Aug 2025, Jiemian

Share price

RMB 7.24

May 2025, Simply Wall St

Share price

Above RMB 10

2022, Jiemian

Market cap, derived

Approx. RMB 7.66bn

31 Jul 2026

P/E on FY2025 EPS, derived

Approx. 87x

31 Jul 2026

P/E on TTM to Q1 2026, derived

Approx. 117x

31 Jul 2026

Analyst coverage

None submitting estimates

Simply Wall St

Credit ratings

None (no listed bonds)

FY2025 AR: corporate bonds not applicable

Dividend per share (MYR Bn)

FY2021

FY2022

Cash dividend per share

0.20—

Analyst Conclusions

Guidance. Management gives no annual targets; the only forward data is the H1 2026 pre-announcement (net profit RMB 220–250M; non-recurring-adjusted RMB 210–240M). There is no sell-side consensus.

Bull case

  1. The H1 2026 rebound (Q2 implied RMB 186–216M) suggests run-rate earnings well above FY2025, and FY2021 proved the asset can earn over RMB 2bn at cycle peaks.

  2. Downstream VAM/EVA and DMC, if funded at RMB 1.6bn, shift the mix toward higher-value products with import-substitution demand.

  3. A strong SOE parent, low leverage and full float since April 2026 provide a stable platform.

Bear case

  1. Structural overcapacity (over 15 Mt, with downstream growth of 5–7%) caps mid-cycle margins; FY2023 and FY2025 show how thin trough earnings are.

  2. Up to 30% dilution and roughly three-year build times push returns out; the 2025 attempt failed.

  3. Licensed technology, falling R&D and related-party flows to the parent weaken the minority-investor case.

Catalysts and monitorables (next 12 months): H1 2026 report detail and Q3 2026 results (late October); shareholder vote, SSE review and CSRC registration of the 2026 placement; acetic acid and coal price spreads; new industry capacity commissioning; any further related-party transactions; FY2026 dividend.

Analyst verdict.

Jiangsu SOPO Chemical, the listed core of the state-owned SOPO Group, is a competently run but structurally challenged commodity producer. Its 1.2-million-tonne acetic acid platform gives genuine scale, and its balance sheet remains conservative, but the five-year record demonstrates that earnings are almost entirely a function of the acetic acid spread rather than company-specific advantage. Gross margin moved from about 42% to about 5% in four years as Chinese capacity surged, and the company has neither coal integration nor proprietary technology to defend returns through the trough.

The 2026 rebound is real but price-driven. If H1 2026 guidance holds, annualised profit could recover toward or above the FY2024 level, yet the stock already trades on a high multiple of depressed trailing earnings, and investors should treat the recovery as cyclical rather than structural.

The investment debate therefore turns on the downstream programme. VAM/EVA and electronic-grade DMC are logical extensions of the methanol and acetic acid chain and address real import-substitution and energy-transition demand. However, the projects rely on licensed foreign technology, enter markets where larger competitors are also adding capacity, require up to 30% dilution, and have a history of delay; the first funding attempt was withdrawn in November 2025. The related-party acquisition of the VAM licence from the parent drew formal minority-investor scrutiny.

On balance, SOPO is a cyclical trading vehicle rather than a compounding equity. The asymmetric upside lies in a sharp acetic acid upturn coinciding with successful placement execution; the downside lies in persistent overcapacity combined with dilution at depressed prices. Monitoring the placement's approval and pricing, quarterly acetic acid realisations, and whether management restores R&D investment will be decisive. Absent sell-side coverage, investors should rely directly on the quarterly operating-data filings, which provide the most timely read on volumes and realised prices.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleNotes

Shao Shouyan (邵守言)

Chairman

Chaired 10th board meetings in 2025–2026; director since at least 2020; recused as related director on SOPO Group transactions, indicating a group-level role

Ma Kehe (马克和)

Director

Director since at least 2020; recused as related director in Feb 2026

Chen Zhilin

General Manager / CEO

Per Simply Wall St; not cross-verified

Hu Zonggui (胡宗贵)

Former director/chairman era (2020 board)

Listed on 2020 placement report

Fan Liming, Fan Ming

Directors on 2020 board

—

Kong Yusheng, Wu Junmin

Directors on 2020 board (likely independents)

—

Major Shareholders

HolderShares%

Jiangsu SOPO (Group) Co., Ltd.

867,603,65274.29

Free float and other holders

approx. 300,239,232

approx. 25.71

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning

Hualu Hengsheng (600426)

Acetic acid, DMC, coal chemicals

Much larger, lower-cost integrated coal chemical leader

Shanghai Huayi / Wujing Chemical

Acetic acid, methanol

Large Shanghai SOE

Yankuang Lunan Chemical (Shandong Energy)

Acetic acid, esters

Coal-integrated

Celanese (Nanjing)

Acetic acid, VAM, EVA

Global technology leader

BP-YPC / BP-SECCO JVs

Acetic acid

Multinational JV capacity

Tianjin Bohai Yongli

Acetic acid

Northern SOE

Henan Longyu / Shaanxi Yanchang

Acetic acid

Coal-region producers

Guangxi Huayi

Acetic acid, coal chemicals

Southern capacity

Wanhua, Rongsheng, Sinopec, Lianhong

VAM / EVA

Future competitors in planned downstream lines

Shida Shenghua (603026), Oriental Shenghong

DMC / electrolyte solvents

Future competitors in DMC

Recent Developments

--

Company Snapshot

$802.5M

Revenue

2,039

Employees

1958

Founded

SWOT Analysis

Strengths

  • 1.2 Mt/yr acetic acid and 250 kt/yr ethyl acetate capacity, among industry leaders (FY2025 AR).
  • Conservative balance sheet: net cash RMB 267M at FY2025; liability ratio 17.69% in mid-2024.
  • Strong SOE parent with 74.29% stake and demonstrated support (2024 share-buying plan).
  • Proven cyclical earnings power: RMB 2.40bn net profit in FY2021.
  • Integrated methanol supply (output +64.94% in FY2024).
  • Exclusive Chinese DuPont ethylene-route VAM licence (company claim, 2026 placement plan).

Weaknesses

  • Approx. 85–90% revenue concentration in acetic acid and derivatives (Q4 2024/Q1 2025 data).
  • Gross margin 5.5% in FY2025 vs 41.6% in FY2021.
  • R&D cut from RMB 271M (FY2022) to RMB 109M (FY2025).
  • Growth technologies entirely licensed from abroad (TMTPost).
  • Related-party dependence on parent (licence purchase, land, daily transactions).
  • Q4 2025 loss and Q1 2026 profit of only RMB 34M show thin trough earnings.

Opportunities

  • H1 2026 price recovery: net profit guided RMB 220–250M.
  • VAM import substitution in high-end photovoltaic grades (Securities Daily).
  • Electronic-grade DMC for battery electrolytes (100 kt/yr planned).
  • Export development to absorb domestic surplus.
  • Industry rationalisation of older high-cost capacity under carbon policy.
  • Chlor-alkali supply discipline lifting segment returns.

Threats

  • Over 2 Mt of new Chinese acetic acid capacity in H1 2025 alone.
  • Placement dilution of up to 350.35M shares (30% of share count).
  • Execution risk: the 2025 placement was withdrawn; the VAM project had been delayed for roughly four years.
  • Coal price volatility.
  • Energy-consumption and carbon policy constraints.
  • Downstream VAM/EVA and DMC capacity additions by larger competitors.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15 Apr 2025FY2024 results: revenue RMB 6.40bn, net profit RMB 213MRecovery year confirmed
15 Apr 2025FY2024 dividend RMB 0.5 per 10 shares proposedLow payout
15 Apr 2025Q1 2025 net profit RMB 57.1M, +121% YoYStrong start
15 Apr 2025BDO China Shu Lun Pan reappointedAudit continuity
19 Apr 2025Parent's exchangeable bonds mature; 233M shares releasedRemoves overhang
Aug 2025H1 2025 net profit RMB 102M, -13% YoY; acetic output +8.9%Price pressure
13 Aug 2025RMB 1.5bn placement plan for VAM/EVAShares fall two days
22 Aug 2025200M parent shares unpledgedLower governance risk
28 Oct 2025Q3 2025: 9M revenue RMB 4.66bn (-5.7%), net profit RMB 126M (-39%)Deterioration
15 Nov 2025Reply to SSE inquiry on placementProcess step
Nov 2025Placement terminatedFunding uncertainty
12 Feb 2026RMB 48.64M land purchase from parent approvedRelated-party flow
10 Apr 2026Last split-share restricted shares listedFull float
17 Apr 2026FY2025 results: revenue RMB 5.86bn, net profit RMB 88.4MQ4 2025 loss implied
17 Apr 2026FY2025 dividend RMB 0.4 per 10 shares proposedLower payout
18 Apr 2026Q1 2026 report: net profit approx. RMB 34MWeak trough
18 Apr 2026Q1 2026 operating data announcedDisclosure
27 May 2026New RMB 1.6bn placement plan incl. DMCStrategy re-launch
Jun 2026FY2025 AGM approves annual report, related-party framework, placement eligibilityShareholder approval
25 Jun 2026Zhenjiang SASAC approves placementKey approval
13 Jul 2026H1 2026 net profit guided RMB 220–250M (+116–145%)Price-led rebound
14 Jul 2026Limit-up openMarket reaction
31 Jul 2026Share price RMB 6.56Up approx. 26% vs 13 Jul close
Aug 2026Verify against guidance
26 Aug 2026Q2 2026 operating data announcedDisclosure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue as reported fell from CNY 8,004 Mn in FY2021 to CNY 5,856 Mn in FY2025.
Jiangsu SOPO (Group) Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue as reported8,0047,1725,4066,4035,856
Operating revenue7,5996,9915,2296,3465,770
Cost of revenue4,6716,1104,9965,8425,536
Gross profit3,3331,062410560320

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.